Cytosorbents Corp
For the period ended Dec 31, 2023. Filed Mar 15, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 15, 2024
CTSO$4.87-9.3%Stored close · as of Nov 13, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations and Comprehensive Loss
Checking your notes…
| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| · · Year ended · · Year ended · · Year ended | |||||||||
| · · December 31, · · December 31, · · December 31, | |||||||||
| · 2023 · · 2022 · · 2021 | |||||||||
| Revenue: · · · | |||||||||
| CytoSorb sales | | $31,015,268 | | $28,572,709 | | $39,996,700 | |||
| Other sales | | | 69,685 | | | 787,201 | | | 111,867 |
| Total product sales | | | 31,084,953 | | | 29,359,910 | | | 40,108,567 |
| Grant income | | | 5,264,426 | | | 5,328,899 | | | 3,056,960 |
| Total revenue | | | 36,349,379 | | | 34,688,809 | | | 43,165,527 |
| Cost of revenue | | | 13,957,356 | | | 13,955,752 | | | 11,047,350 |
| Gross profit | | | 22,392,023 | | | 20,733,057 | | | 32,118,177 |
| Operating expenses: | | | | | | ||||
| Research and development | | | 15,728,915 | | | 15,118,907 | | | 16,380,930 |
| Legal, financial and other consulting | | | 4,272,296 | | | 2,847,899 | | | 2,731,515 |
| Selling, general and administrative | | | 33,600,065 | | | 34,288,130 | | | 35,750,477 |
| Total operating expenses | | | 53,601,276 | | | 52,254,936 | | | 54,862,922 |
| Loss from operations | | | (31,209,253) | | | (31,521,879) | | | (22,744,745) |
| Other income (expense): | | | | | | | |||
| Interest income (expense), net | | | (157,891) | | | 132,597 | | | 28,007 |
| Gain (loss) on foreign currency transactions | | | 1,949,257 | | | (2,448,583) | | | (2,577,913) |
| Miscellaneous income (expense) | | | 96,754 | | | (67,303) | | | — |
| Total other income (expense), net | | | 1,888,120 | | | (2,383,289) | | | (2,549,906) |
| | | | | | | ||||
| Loss before benefit from income taxes | | | (29,321,133) | | | (33,905,168) | | | (25,294,651) |
| | | | | | | | | | |
| Benefit from income taxes | | 813,739 | | 1,092,585 | | 736,003 | |||
| | | | | | | ||||
| Net loss attributable to common stockholders | | $(28,507,394) | | $(32,812,583) | | $(24,558,648) | |||
| | | | | | | | | | |
| Basic and diluted net loss per common share | | $(0.64) | | $(0.75) | | $(0.57) | |||
| | | | | | | | | | |
| Weighted average number of shares of common stock outstanding | | | 44,656,391 | | | 43,573,215 | | | 43,359,186 |
| | | | | | | | | | |
| Comprehensive loss: | | | | | | | | | |
| Net loss | | $(28,507,394) | | $(32,812,583) | | $(24,558,648) | |||
| Other comprehensive income (loss): | | | | | | | | ||
| Foreign currency translation adjustment | | | (1,799,874) | | | 1,803,610 | | | 2,259,663 |
| Comprehensive loss | | $(30,307,268) | | $(31,008,973) | | $(22,298,985) | |||
CONSOLIDATED STATEMENTS OF CHANGES IN
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.